Tags: Drug.
Tocilizumab (INN or atlizumab developed by Hoffmann–La Roche and Chugai and sold under the trade names Actemra and RoActemra) is an immunosuppressive drug mainly for the treatment of rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis a severe form of RA in children. It is a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R).